http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shin Nishio,Satomi Aihara,Mototsugu Shimokawa,Akira Fujishita,Shuichi Taniguchi,Toru Hachisuga,Shintaro Yanazume,Hiroaki KOBAYASHI,Fumihiro Murakami,Fumitaka Numa,Kohei Kotera,Naofumi Okura,Naoyuki To 대한부인종양학회 2018 Journal of Gynecologic Oncology Vol.29 No.5
Objective: Palonosetron is effective for the management of acute and delayed chemotherapy-induced nausea and vomiting (CINV). While emetogenic carboplatin-based chemotherapy is widely used to treat gynecologic cancers, few studies have evaluated the antiemetic effectiveness of palonosetron in this setting. Methods: A multicenter, single-arm, open-label phase II trial was conducted to evaluate the safety and effectiveness of palonosetron in controlling CINV in patients with gynecologic cancer. Chemotherapy-naïve patients received intravenous palonosetron (0.75 mg/body) and dexamethasone before the infusion of carboplatin-based chemotherapy on day 1. Dexamethasone was administered (orally or intravenously) on days 2–3. The incidence and severity of CINV were evaluated using the patient-completed Multinational Association of Supportive Care in Cancer Antiemesis Tool and treatment diaries. The primary endpoint was the proportion of patients experiencing complete control (CC) of vomiting, with “no rescue antiemetic medication” and “no clinically significant nausea” or “only mild nausea” in the delayed phase (24–120 hours post-chemotherapy). Secondary endpoints were the proportion of patients with a complete response (CR: “no vomiting” and “no rescue antiemetic medication”) in the acute (0–24 hours), delayed (24–120 hours), and overall (0–120 hours) phases, and CC in the acute and overall phases. Results: Efficacy was assessable in 77 of 80 patients recruited. In the acute and delayed phases, the CR rates the primary endpoint, were 71.4% and 59.7% and the CC rates, the secondary endpoint, were 97.4% and 96.1%, respectively. Conclusion: While palonosetron effectively controls acute CINV, additional antiemetic management is warranted in the delayed phase after carboplatin-based chemotherapy in gynecologic cancer patients (Trial registry at UMIN Clinical Trials Registry, UMIN000012806).
Kensuke Hori,Shin Nishio,Kimio Ushijima,Yuka Kasamatsu,Eiji Kondo,Kazuhiro Takehara,Kimihiko Ito 대한부인종양학회 2021 Journal of Gynecologic Oncology Vol.32 No.4
Objective: To determine the safety and efficacy of dose-dense (dd) paclitaxel (PTX) and carboplatin (CBDCA) in treating advanced or recurrent endometrial cancer. Methods: Women aged 20–75 years with histologically confirmed endometrial cancer, the International Federation of Gynecology and Obstetrics (FIGO) stage III disease with some residual tumor, FIGO stage IV disease, recurrence after front-line curative treatment, or recurrence after second-line chemotherapy or radiotherapy were enrolled in this study. PTX (80 mg/m2) was administered intravenously (IV) to every participant on days 1, 8, and 15, and CBDCA (area under the curve of 5) was administered IV on day 1 once every 3 weeks until the disease progressed, unacceptable adverse events occurred, or consent was withdrawn. The primary endpoint was the response rate (RR), while the secondary endpoints were progression-free survival, overall survival, and adverse effects. Results: Forty-eight participants were enrolled, and 46 were eligible to receive treatment. The patients' median age was 61 years (range, 43–76 years). Twenty-two participants had experienced recurrence, and the remaining patients had primary advanced endometrial cancer. There were 10 cases of serous carcinoma, 3 cases of endometrioid carcinoma G3, 2 cases of carcinosarcoma, and 2 cases of clear-cell carcinoma according to histology. Twenty- nine participants (63.0%) received ≥6 cycles of chemotherapy. The RR (complete, 13 cases; partial, 20 cases) was 71.3% (95% confidence interval: 59.0%–84.5%). Conclusion: The dd PTX with CBDCA is feasible and available as a treatment option for advanced or recurrent endometrial cancer. Trial Registration: UMIN Clinical Trials Registry Identifier: UMIN000017138
Kouichiro Kawano,Naotake Tsuda,Shin Nishio,Koji Yonemoto,Kazuto Tasaki,Rurika Tasaki,Kimio Ushijima 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.5
Objective: To identify key factors for predicting positive cone margin and appropriate conelength. Methods: We retrospectively reviewed the margin status of patients who received conizationwith high grade cervical intraepithelial neoplasia, along with other factors such as patientage, parity, preoperative cytology, size of disease, type of transformation zone, and conelength from patient records. Cut-off value of cone length was analyzed in women youngerthan 40 years old because we design conization with minimum length especially forwomen who wish for future pregnancy. Cut-off value of cone length was defined as lengthcorresponds to estimated probability of positive cone margin equal to 0.1 by logisticregression analysis with variables selected by stepwise methods. Results: Among 300 patients, 75 patients had positive cone margin. Multivariable analysisrevealed that squamous cell carcinoma at preoperative cytology (p=0.001), 2 or morequadrant disease (p=0.011), and shorter cone length (p<0.001) were risk factors for positivecone margin. Stepwise methods identified cone length and size of lesion as importantvariables. With this condition, cut-off value of cone length was estimated as 15 mm in singlequadrant disease and 20 mm in 2 or more quadrant disease, respectively. Conclusion: We identified the independent risk factors of positive cone margin and identifiedthe cut-off value of cone length to avoid positive cone margin in women younger than 40years old. Conization should be performed not only according to colposcopic findingsincluding type of transformation zone but size of disease and cone length.
( Kimio Ushijima ),( Shuji Takemoto ),( Kouichiro Kawano ),( Shin Nishio ),( Atsumu Terada ),( Naotake Tsuda ),( Gonosuke Sonoda ),( Syun Ichiro Ota ),( Toshiharu Kamura ) 대한산부인과학회 2012 Obstetrics & Gynecology Science Vol.55 No.4
Type III radical abdominal hysterectomy (RAH) is standard care for early stage cervical cancer. For the past few decades, there has been a remarkable shift from surgery to radiation, in the treatment choice for stage 1b2 and 2b cervical cancer in Japan. It is still controversial, however because some of those cases recommended RAH as a suitable treatment strategy. About 8% to 10% of RAH are abandoned because of tumor status. Recent preoperative screening cannot always detect them preoperatively. Various kinds of new surgical instruments, such as bipolar scissors and the electro vessel sealing system LigaSure have contributed to reducing the operation time and blood loss, in performing RAH. Furthermore, various kinds of devices are on the market. Surgeons should choose suitable instruments depending on the state of the disease and the patient.
Review : Epithelial borderline ovarian tumor: Diagnosis and treatment strategy
( Kimio Ushijima ),( Kouichiro Kawano ),( Naotake Tsuda ),( Shin Nishio ),( Atsumu Terada ),( Hiroyuki Kato ),( Kazuto Tasaki ),( Ken Matsukuma ) 대한산부인과학회 2015 Obstetrics & Gynecology Science Vol.58 No.3
Epithelial borderline ovarian tumors (BOT) are distinctive from benign tumors and carcinoma. They occur in younger women more often than carcinoma, and there is some difficulty making correct diagnosis of BOT. Two subtypes of BOT, serous and mucinous borderline tumor have different characteristics and very different clinical behavior. Serous borderline tumor (SBT) with micropapillary pattern shows more incidence of extra ovarian disease and often coexists with invasive implant. SBT with micropapillary pattern in advanced stage has showed a worse prognosis than typical SBT. Huge mucinous borderline tumors have histologic heterogeneity, and the accuracy of frozen section diagnosis is relatively low. Extensive sampling is required to reach a correct pathological diagnosis. Mucinous adenoma (intestinal type) also runs the risk of recurrence after cystectomy, or intraoperative rupture of cyst. Laparoscopic procedure for BOT has not increased the risk of recurrence. Fertility preserving procedures are generally accepted, except in advanced stage SBT with invasive implants. Only cystectomy shows a significant risk of recurrence. Re-staging surgery and full staging surgery is not necessary for all BOT. We should not attempt to treat them uniformly, by the single diagnosis of “borderline tumor”. It depends on histologic type. Close communication with the pathologist is necessary to gain more detail and ask more pathological samples in order to make the optimal treatment strategy for each individual patients.